PDCD1 and graft versus host disease: While outcomes have been favorable regarding cancer-free progression, anti-PD-1 treatment after HCT is associated with the induction of alloimmunity in the form of T cell-mediated acute graft-vs.-host disease (aGVHD) (67, 69).